Value-Based Contracts: Medicaid Best Price Concerns Could Be Eased With CMS Guidance
Executive Summary
Absent any legislative remedy, an administrative fix could provide manufacturers with confidence that value-based arrangements won’t trigger a new best price, Duke Margolis policy experts propose.
You may also be interested in...
Gene Therapy Payment Models Could Be One Focus For 'Cures II'
House Republicans are eager to keep working on legislation to permit innovative payment models for curative gene and cell therapies. Democrats, for now, are focused on other priorities.
Accelerated Approval For Medicare Coverage? FDA Model Could Be Useful For Value-Based Agreements
Centers for Medicare & Medicaid Innovation could enable outcomes-based contracting for novel, 'curative' therapies follow something like the FDA’s Accelerated Approval model, former top HHS official suggests.
Curative Gene Therapy Coverage May Need Government-Funded Risk Pools
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.